Published in Int J Nanomedicine on July 08, 2015
Warburg effect, hexokinase-II, and radioresistance of laryngeal carcinoma. Oncotarget (2016) 0.75
Chaperone-mediated autophagy substrate proteins in cancer. Oncotarget (2017) 0.75
Why do cancers have high aerobic glycolysis? Nat Rev Cancer (2004) 20.60
Glycolysis inhibition for anticancer treatment. Oncogene (2006) 6.55
ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science (2008) 5.54
Spheroid-based drug screen: considerations and practical approach. Nat Protoc (2009) 4.01
Epidermal growth factor receptor targeting in cancer. Semin Oncol (2006) 3.84
Causes and consequences of increased glucose metabolism of cancers. J Nucl Med (2008) 3.79
A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release (2008) 3.27
Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell (2013) 2.55
Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun (2004) 2.29
Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett (2001) 2.11
Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J (2005) 1.96
Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem (2001) 1.84
3D cell culture: a review of current approaches and techniques. Methods Mol Biol (2011) 1.68
Monolayer and spheroid culture of human liver hepatocellular carcinoma cell line cells demonstrate distinct global gene expression patterns and functional phenotypes. Tissue Eng Part A (2009) 1.64
Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. Biochem J (2009) 1.45
Spheroid culture as a tool for creating 3D complex tissues. Trends Biotechnol (2013) 1.40
3-Bromopyruvate: targets and outcomes. J Bioenerg Biomembr (2012) 1.27
Binding and interstitial penetration of liposomes within avascular tumor spheroids. Int J Cancer (2004) 1.21
Influence of glucose and oxygen supply conditions on the oxygenation of multicellular spheroids. Br J Cancer (1986) 1.14
A translational study "case report" on the small molecule "energy blocker" 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside. J Bioenerg Biomembr (2012) 1.09
Achievements and unmet needs in the management of advanced ovarian cancer. Gynecol Oncol (2010) 1.06
Mathematical modelling of drug transport in tumour multicell spheroids and monolayer cultures. Math Biosci (2003) 0.97
Engineering lipid vesicles of enhanced intratumoral transport capabilities: correlating liposome characteristics with penetration into human prostate tumor spheroids. J Liposome Res (2005) 0.92
A quality by design (QbD) case study on liposomes containing hydrophilic API: II. Screening of critical variables, and establishment of design space at laboratory scale. Int J Pharm (2011) 0.90
Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids. Biotechnol Bioeng (1999) 0.90
Liposomes: the Babraham connection. Chem Phys Lipids (1993) 0.88
Epidermal growth factor receptor-targeted gelatin-based engineered nanocarriers for DNA delivery and transfection in human pancreatic cancer cells. AAPS J (2008) 0.88
Sensitivities of monolayers and spheroids of the human bladder cancer cell line MGH-U1 to the drugs used for intravesical chemotherapy. Cancer Res (1989) 0.84